New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2013
13:05 EDTSNY, TSPTFDA doesn't require labeling changes for Intermezzo in review of sleep aids
The FDA announced earlier that it is requiring Sanofi (SNY), the manufacturer of Ambien, and some makers of other insomnia drugs that contain zolpidem, to lower the recommended dose. The FDA said the recommended bedtime dose should be lowered because new data show that blood levels in some patients may be high enough the morning after use to impair activities that require alertness, including driving. The FDA said recommended doses of Transcept Pharmaceuticals' (TSPT) Intermezzo, a lower dose zolpidem product approved for middle-of-the-night awakenings, are not changing. At the time of Intermezzos approval in November 2011, the label already recommended a lower dosage for women than for men, the FDA noted. In afternoon trading, shares of Transcept rose 16c, or 3.04%, to $5.43. Reference Link
News For TSPT;SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 9, 2014
11:19 EDTSNYSanofi reportedly ready to make acquisitions in animal medicine, Bloomberg says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use